Brought to you by 
Merck will develop Dov depression candidates
01 Jun 2009
Executive Summary
Dov Pharmaceutical (in-licenses and develops compounds for treating CNS and CV diseases that involve alterations in neuronal processing) is licensing two clinical-phase triple uptake inhibitors to Merck for development against depression and other psychiatric illnesses. Dov's 8K of 9/22/04 adds that Merck also received rights of first refusal regarding another triple uptake inhibitor, DOV 102,677 (preclinical; for anxiety or depression) under certain circumstances and for additional payment.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com